IPCA Laboratories Limited (NSE: IPCALAB) stock has cleared its 6-month resistance trendline, moving up 5% intraday to ₹1732.7.
Ipca Laboratories (IPCALAB) partners with Bhami’s Research Laboratory for global licensing of novel subcutaneous biologics delivery technology.